Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, highlighting significant growth for its flagship medication, Filspari. The company achieved quarterly net product sales of $126.6 million and a full-year total of $410.5 million, with Filspari alone generating $322 million in 2025, which was a 144% increase year-over-year.

This growth was supported by expanded physician confidence, favorable reimbursement pathways covering 96% of the patient population, and updated clinical guidelines. The company is focused on several key clinical and regulatory milestones, most notably the potential expansion of Filspari into FSGS (Focal Segmental Glomerulosclerosis). While the FDA shifted the target action date for the Filspari SNDA to April 13 this year, management expressed confidence that proteinuria remains a valid surrogate endpoint for full approval.

Travere Therapeutics Inc. (NASDAQ:TVTX) has also resumed site activation for the Phase 3 Harmony study of Pegtobatinase to deliver the first disease-modifying therapy for classical homocystinuria. To support these upcoming launches and existing demand, the company has expanded its field team to over 100 personnel, targeting the high prescriber overlap between IgA nephropathy and FSGS.

Travere Therapeutics Inc. (NASDAQ:TVTX) is a biopharmaceutical company that identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the US.

While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.